ERBB2 and breast carcinoma: This synergy between NK cells and antibodies, characterized by upregulated cytokine profiles and robust NK cell activation, validates the therapeutic potential of NK cells for targeting HER2‐positive breast cancers, and lays the foundation for optimizing NK cell‐based immunotherapy.